Health Care · Surgical & Medical Instruments & Apparatus

RCEL AVITA Medical, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 176230364 filings
Russell 2000

RCEL at a glance

AVITA Medical, Inc. (RCEL, SEC CIK 1762303) filed its latest 20-F annual report on October 31, 2019 and Form 4 insider filings as recently as August 24, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), AVITA Medical, Inc. (RCEL) reported revenue of $71.6 million (up 11.5% from FY2024) and a net loss of $48.6 million. Diluted EPS was -$1.74.
  • As of September 30, 2026, 20 institutional investment managers tracked by SignalX reported holding AVITA Medical, Inc. (RCEL) shares worth $48.2 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by O'Toole David D on June 12, 2026 of 2,000 shares at $3.97 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$71.6M
+11.5% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
20 funds
$48.2M · +5 vs prior quarter
Latest 8-K
Nov 13, 2026
Item 7.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Jun 30, 2026

Risk Factors

  • No material risk-factor changes from the 2025 Annual Report
  • Carried-forward business, liquidity, operational, regulatory, and market risks remain applicable
  • Potential adverse effects on financial condition, liquidity, results of operations, and capital position
  • Actual results may differ materially from historical results and forward-looking statements

AI summary of the RCEL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 13, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Perceptive received 119,375 shares after cashless exercise of a warrant covering 150,000 shares
  • Company withheld 30,625 shares for the Perceptive Warrant exercise price, limiting net dilution
Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 results announced for the quarter ended September 30, 2026
  • Financial details and management commentary contained in Exhibit 99.1 press release

Item EX-99.1: Item EX-99.1

  • Q3 revenue $26.1M, up 53% year over year and 20% sequentially, led by RECELL and growing Cohealyx adoption
  • Gross margin 84.0%, up from 81.3%, while operating expenses reached $24.6M, limiting operating leverage
Filed Nov 2, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Perceptive exercised its warrant for up to 500,000 shares through a cashless exercise
  • Company withheld 112,284 shares for the exercise price, limiting net issuance

AI summaries of RCEL 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for RCEL

Don't miss the next RCEL filing

  • Alerts as it files. A push when RCEL files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut RCEL, by share count.
  • Ask anything. An AI agent that reads every RCEL filing and answers with sources.

RCEL alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
O'Toole David DAJun 12, 2026$3.97
O'Toole David DBuyJun 12, 2026$3.97
Woody Joseph FralinBuyJun 9, 2026$4.20
Woody Joseph FralinBuyJun 9, 2026$4.18
Woody Joseph FralinBuyJun 9, 2026$4.00
Woody Joseph FralinBuyJun 3, 2026$4.10
Woody Joseph FralinBuyJun 3, 2026$4.09
Woody Joseph FralinBuyJun 2, 2026$4.21

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$50.1M$64.3M$71.6M
Gross Profit-$55.2M$58.8M
Operating Income--$56.6M-$42.5M
Net Income--$61.8M-$48.6M
Gross Margin-85.8%82.1%
Op. Margin--88.1%-59.4%
Net Margin--96.3%-67.8%
Balance Sheet
Total Assets-$79.7M$56.4M
Equity-$4.5M-$16.6M
ROE--1374.6%291.8%
Per Share
EPS-$-2.39$-1.74
Cash Flow
Operating CF--$48.9M-$31.2M
CapEx$1.4M$9.2M$1.0M

Source: XBRL data in AVITA Medical, Inc. (RCEL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate RCEL share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
RCEL shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202620$48.2M
Q2 202615$11.8M
Q1 202617$13.7M
Q4 202517$12.7M
Q3 202517$19.2M
Q2 202521$27.7M
Q1 202518$23.7M
Q4 202413$31.9M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 138 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

RCEL filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 20-F, 6-K

FormFiling dateAnalysisSEC
8-KNov 13, 2026Analysis-
8-KNov 5, 2026Analysis-
8-KNov 2, 2026Analysis-
4Aug 24, 2026--
8-KAug 11, 2026Analysis-
10-QAug 6, 2026Analysis
8-KAug 6, 2026Analysis-
8-KAug 6, 2026Analysis-
4Jun 12, 2026--
4Jun 10, 2026-
4Jun 9, 2026-
8-KJun 8, 2026Analysis
4Jun 5, 2026-
4Jun 4, 2026-
4Jun 4, 2026-
4Jun 4, 2026-
4Jun 4, 2026-
4Jun 4, 2026-
4Jun 4, 2026-
8-KJun 4, 2026Analysis
4Jun 3, 2026-
4Jun 1, 2026-
4Jun 1, 2026-
4May 20, 2026-
4May 19, 2026-

Related Health Care companies

All Health Care →

RCEL SEC filings: frequently asked questions

Which institutions hold RCEL stock?

As of September 30, 2026, the largest AVITA Medical, Inc. (RCEL) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($15.7 million), BlackRock ($6.6 million), Two Sigma Investments ($5.9 million), Millennium Management ($4.3 million), Goldman Sachs Group ($3.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was RCEL's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), AVITA Medical, Inc. (RCEL) reported revenue of $71.6 million (up 11.5% from FY2024) and a net loss of $48.6 million. Diluted EPS was -$1.74. The figures come from the XBRL data in the 10-K.

What did RCEL report in its latest 8-K?

AVITA Medical, Inc. (RCEL) filed an 8-K on November 13, 2026 reporting Item 7.01 (Regulation FD Disclosure). Perceptive received 119,375 shares after cashless exercise of a warrant covering 150,000 shares.

What are the latest RCEL SEC filings?

AVITA Medical, Inc. (RCEL) filed its latest 20-F annual report on October 31, 2019 and a Form 4 insider filing on August 24, 2026.

What is RCEL's SEC CIK number?

AVITA Medical, Inc. (RCEL)'s SEC Central Index Key (CIK) is 1762303. EDGAR lists every RCEL filing under that number.

Ask anything about RCEL

The research agent reads RCEL's filings, financials, insider trades and 13F holders, then answers with sources.